Should I buy TransMedics Group, Inc. (TMDX) stock or is it too late?

TransMedics Group, Inc. · Health Care · price $92

See the full TransMedics Group, Inc. (TMDX) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: UBS — 58% of its targets hit on this sector (74 calls tested). It aims for $77 (-16 %), call made on August 6, 2026, maturing on August 6, 2027 (22 d ago).

The 1 reliable analyst $77-16 %

The 6 other firms $103+12 %

How to read it: the 1 reliable firms are not filtered by optimism — 0 aim above the price, 1 below, hence their $77 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on TransMedics Group, Inc.

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Canaccord Genuity	58 %	+46.0 %	12	$124 +35%
Oppenheimer	55 %	+30.5 %	11	$175 +91%
JP Morgan	57 %	+22.2 %	7	$149 +62%
Piper Sandler	33 %	+3.5 %	12	$100 +9%
Cowen & Co.	40 %	+50.1 %	5	—

In short — Should you invest in TransMedics Group, Inc.? Is it too late, still worth it? Analysts are fairly positive (71% buy, median target $100, i.e. +9%), and the most reliable on TMDX targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

71% of analysts rate it a buy (Buy consensus, 7 ratings) — a sign of market conviction.
Median price target $100, i.e. +9% from the current price ($92).
The most reliable firm on TMDX, Canaccord Genuity (58% hit rate, 12 scored calls), targets $124 (call made on June 30, 2026, maturing on June 30, 2027) (+35%) in its most recent call, and $142 (call made on October 14, 2025, maturing on October 14, 2026) (+55%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 7 ratings, 2 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on TMDX

Median target $100 (+9%) · 7 ratings · Buy consensus

Strong Buy00%

Buy571%

Hold229%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in TransMedics Group, Inc. now?

We won't decide for you. The facts: 71% of analysts rate it a buy, median target $100 (+9%), and Canaccord Genuity (most reliable on TMDX, 58%) targets $124. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in TransMedics Group, Inc.?

Not according to analysts: the median target ($100) is still +9% above the current price ($92) (most reliable on TMDX: Canaccord Genuity, 58%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is TransMedics Group, Inc. still worth investing in?

It depends on the gap between the price ($92) and its estimated value: analysts target $100 on median (+9%), with 71% buys (most reliable on TMDX: Canaccord Genuity, 58%). Cross-check with their real reliability on TMDX and the cautions above. Information, not advice.

What's the main risk in buying TMDX?

The consensus is not unanimous: of 7 ratings, 2 are neutral.

→ Go deeper: the full TransMedics Group, Inc. profile (consensus, analyst reliability, price target, performance).